Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer’s Clinical Trial

New York, NY — March 19, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014,…

Anavex Announces $10 Million Private Placement of Convertible Debentures

Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer’s Disease and Advance Product Portfolio New York, NY — March 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types…

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease)

Company to Initiate Pre-Clinical Studies of ANAVEX 2-73 in ALS Models New York, NY — March 10, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced…

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists

Findings Correlate with Positive Phase 1 Safety Data for ANAVEX 2-73 New York, NY — March 4, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences.  Among its conclusions, the report reveals…

Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds

Sigma-1 Receptor Modulation Preventing Neuropathic Pain Induced by Paclitaxel New York, NY — February 26, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company’s anti-cancer and neuropathic pain compounds. …

Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases – Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases

New York, NY — January 23, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer’s. The report demonstrates for the first time, evidenced by human brain…

Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS

New York, NY — January 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer’s disease.  This study…

Anavex CEO Invited to Present at Upcoming Investment Conferences

New York, NY — January 7, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate in the 7th Annual OneMedForum: Investing in Healthcare 2014 (“OneMedForum”) and the Noble Financial Capital Markets (“Noble”) Tenth Annual Equity Conference. OneMedForum…